Racial differences in serum chemokines in prostate cancer patients.
Cancer
; 129(23): 3783-3789, 2023 12 01.
Article
em En
| MEDLINE
| ID: mdl-37698493
ABSTRACT
BACKGROUND:
This study aimed to understand the differential levels of inflammatory chemokines in association with higher prostate cancer incidence and mortality in African American (AA) men than in Caucasians (CA).METHODS:
The authors used a chemokine assay to simultaneously measure 40 chemokines and cytokines levels in the serum of preoperative prostate cancer patients and healthy controls of AA and CA races. Selected chemokines (CXCL2, CXCL5, and CCL23) serum level was validated in 211 serum samples from prostate cancer patients and healthy controls. Differential expression of CXCL5 and CCL23 was analyzed using immunohistochemistry in a representative cohort of prostate tumor tissues of AA and CA races.RESULTS:
Race-specific comparisons from 211 serum samples showed significantly higher levels of CXCL2 (control 3104.0 pg/mL vs. cancer 2451.0 pg/mL) and CXCL5 (control 5189.0 pg/mL vs. cancer 5459.0 pg/mL) in AA men than in CAs (CXCL2; control 1155.0 pg/mL vs. cancer 889.3 pg/mL, and CXCL5; control 1183.0 pg/mL vs. cancer 977.5 pg/mL). CCL23 differed significantly within and between the races with a lower level in AA cancer cases (454.5 vs. 966.6 pg/mL) than healthy controls (740.5 vs. 1263.0 pg/mL). Patient age, prostate-specific antigen, or Gleason scores were not significantly associated with these chemokines. Immunostaining for CXCL5 and CCL23 in a representative cohort of archival prostate tissues displayed significantly higher CXCL5 in prostate tumors than in adjacent benign tissues, whereas CCL23 was nondetectable in most of the analyzed tumor tissues.CONCLUSION:
Lower levels of CCL23 in AA prostate cancer patient sera and tumor tissues and high CXCL2 and CXCL5 may contribute to aggressive prostate cancer, as often seen in AA men. The disproportionate levels of serum chemokines associated with race warrant further exploration to improve equitability in precision oncology to benefit prostate cancer patients.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Medicina de Precisão
Limite:
Humans
/
Male
Idioma:
En
Revista:
Cancer
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos